Implantable device could allow doctors to test cancer drugs in patients before prescribing chemotherapy
More than 100 drugs have been approved to treat cancer, but predicting which ones will help a particular patient is an inexact science at best.
A new device developed at MIT may change that. The implantable device, about the size of the grain of rice, can carry small doses of up to 30 different drugs. After implanting it in a tumor and letting the drugs diffuse into the tissue, researchers can measure how effectively each one kills the patient’s cancer cells.
Such a device could eliminate much of the guesswork now involved in choosing cancer treatments, says Oliver Jonas, a postdoc at MIT’s Koch Institute for Integrative Cancer Research and lead author of a paper describing the device in the April 22 online edition of Science Translational Medicine.
“You can use it to test a patient for a range of available drugs, and pick the one that works best,” Jonas says.
The paper’s senior authors are Robert Langer, the David H. Koch Professor at MIT and a member of the Koch Institute, the Institute for Medical Engineering and Science, and the Department of Chemical Engineering; and Michael Cima, the David H. Koch Professor of Engineering at MIT and a member of the Koch Institute and the Department of Materials Science and Engineering.
Putting the lab in the patient
Most of the commonly used cancer drugs work by damaging DNA or otherwise interfering with cell function. Recently, scientists have also developed more targeted drugs designed to kill tumor cells that carry a specific genetic mutation. However, it is usually difficult to predict whether a particular drug will be effective in an individual patient.
In some cases, doctors extract tumor cells, grow them in a lab dish, and treat them with different drugs to see which ones are most effective. However, this process removes the cells from their natural environment, which can play an important role in how a tumor responds to drug treatment, Jonas says.
“The approach that we thought would be good to try is to essentially put the lab into the patient,” he says. “It’s safe and you can do all of your sensitivity testing in the native microenvironment.”
The device, made from a stiff, crystalline polymer, can be implanted in a patient’s tumor using a biopsy needle. After implantation, drugs seep 200 to 300 microns into the tumor, but do not overlap with each other. Any type of drug can go into the reservoir, and the researchers can formulate the drugs so that the doses that reach the cancer cells are similar to what they would receive if the drug were given by typical delivery methods such as intravenous injection.
After one day of drug exposure, the implant is removed, along with a small sample of the tumor tissue surrounding it, and the researchers analyze the drug effects by slicing up the tissue sample and staining it with antibodies that can detect markers of cell death or proliferation.
Ranking cancer drugs
To test the device, the researchers implanted it in mice that had been grafted with human prostate, breast, and melanoma tumors. These tumors are known to have varying sensitivity to different cancer drugs, and the MIT team’s results corresponded to those previously seen differences.
The researchers then tested the device with a type of breast cancer known as triple negative, which lacks the three most common breast cancer markers: estrogen receptor, progesterone receptor, and Her2. This form of cancer is particularly aggressive, and none of the drugs used against it are targeted to a specific genetic marker.
Using the device, the researchers found that triple negative tumors responded differently to five of the drugs commonly used to treat them. The most effective was paclitaxel, followed by doxorubicin, cisplatin, gemcitabine, and lapatinib. They found the same results when delivering these drugs by intravenous injection, suggesting that the device is an accurate predictor of drug sensitivity.
Read more: How to identify drugs that work best for each patient
The Latest on: Personalized medicine
[google_news title=”” keyword=”Personalized medicine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Personalized medicine
- Personalized 'cocktails' of antibiotics, probiotics and prebiotics hold promise in treating IBS, pilot study findson April 26, 2024 at 3:10 pm
Personalized "cocktails" of antibiotics, probiotics and prebiotics hold great promise in the treatment of a common form of irritable bowel syndrome (IBS), according to research presented at the ESCMID ...
- 'Despite promise, personalized medicine for head and neck cancers facing hurdles'on April 26, 2024 at 3:45 am
Improved efficacy: By identifying specific mutations driving tumour growth, personalized medicine allows for targeted therapies that have a higher success rate compared to ‘one-size-fits-all’ ...
- Moderna and OpenAI Collaborate To Advance mRNA Medicineon April 24, 2024 at 4:11 am
Generative AI will help advance Moderna’s broad and diverse portfolio to maximize the Company’s impact on patients ...
- AI could predict whether cancer treatments will work, experts say: ‘Exciting time in medicine'on April 23, 2024 at 3:00 am
A chemotherapy alternative called immunotherapy is showing promise in treating cancer — and a new artificial intelligence tool could help ensure that patients have the best possible experience.
- 8 Clinical Trials That Will Shape Medicine in 2024on April 22, 2024 at 10:13 am
One of the exciting things about modern medicine is that it is making increasingly rapid advancements in a number of key areas. These advancements could have a major impact on the future of medicine.
- Progesterone Therapy in Demand for Personalized Medicine: Market to Reach US$4.8 Billion by 2034 | Future Market Insights, Inc.on April 22, 2024 at 3:30 am
After extensive research, the progesterone market suggests an upward trajectory from 2024 to 2034, inferring a healthy CAGR of 12.30%. With preliminary valuations of US$ 1.50 billion in 2024, the ...
- How AI can help cancer patients receive personalized and precise treatment fasteron April 16, 2024 at 1:35 pm
Providence and Microsoft are developing research prototype AI tools to sort through growing mountains of patient data.
- Q&A: When will patients see personalized cancer vaccines?on April 16, 2024 at 10:43 am
Catherine Wu has been a pioneer in a promising approach to fight cancer: vaccines that target specific immune-stimulating molecules, known as immunogenic peptides, generated by the distinct genetic ...
- The Future of Breast Cancer Care: Blackwood on Personalized Approacheson April 15, 2024 at 8:01 am
In this episode of Targeted Talks, M. Michele Blackwood, MD, FACS, discusses the current landscape of breast cancer treatment and how personalized medicine with genomic testing is changing the field.
- Predictive & Personalized Medicine Market to Grow at CAGR of 8.2% by 2032on April 11, 2024 at 5:00 pm
According to a recent report by Market.us, the Global Predictive & Personalized Medicine Market size is expected to be worth around USD 692.0 Billion by 2032 from USD 347.2 Billion in 2023, growing at ...
via Bing News